Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma [7]

Journal of the American Academy of Dermatology

Volumn 44, Issue 2, 2001, Pages 312-313

  Acosta, M ^a   Teitelbaum, A ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DENILEUKIN DIFTITOX;

AGED; BACTEREMIA; CAPILLARY LEAK SYNDROME; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOTOXICITY; DISEASE COURSE; EDEMA; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; T CELL LYMPHOMA;

EID: 0035110843     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2001.110643     Document Type: Letter

References (6)

1. Vascular leak syndrome: A side effect of immunotherapy
2. Targeted toxins
3. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity
4. Steroid prophylaxis prevents systemic inflammatory response syndrome (SIRS) in AML patients treated with diphtheria fusion protein
5. 389IL-2 in NHL: Decreased frequency and severity with steroid premedication
6. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkins lymphoma: Effect of an intensive schedule of administration